Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025

Glucotrack, Inc.

2025-Q2 EPS reported $34.81

Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.
Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.
Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.
Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.
Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.